NCT05629364View on ClinicalTrials.gov

A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

January 9, 2024

Study Completion Date

January 9, 2024

Conditions
Dry Eye Disease
Interventions
DRUG

KIO-101

Randomized, Controlled

Trial Locations (1)

4005

Ophthalmic Trials Australia, Teneriffe

Sponsors
All Listed Sponsors
lead

Kiora Pharmaceuticals, Inc.

INDUSTRY

NCT05629364 - A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease | Biotech Hunter | Biotech Hunter